Generic Tygacil Availability

Tygacil is a brand name of tigecycline, approved by the FDA in the following formulation(s):

TYGACIL (tigecycline - injectable;iv (infusion))

  • Manufacturer: PF PRISM CV
    Approval date: June 15, 2005
    Strength(s): 50MG/VIAL [RLD]

Has a generic version of Tygacil been approved?

No. There is currently no therapeutically equivalent version of Tygacil available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tygacil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Tigecycline compositions and methods of preparation
    Patent 7,879,828
    Issued: February 1, 2011
    Inventor(s): Fawzi; Mahdi B. & Zhu; Tianmin & Shah; Syed M.
    Assignee(s): Wyeth LLC
    The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Patent expiration dates:
    • February 5, 2029
      Drug product
  • Crystalline solid forms of tigecycline and methods of preparing same
    Patent 8,372,995
    Issued: February 12, 2013
    Assignee(s): Wyeth LLC
    Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
    Patent expiration dates:
    • October 8, 2030
      Drug product
  • 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
    Patent RE40183
    Issued: March 25, 2008
    Inventor(s): Hlavka; Joseph J. & Sum; Phaik-Eng & Gluzman; Yakov & Lee; Ving J. & Ross; Adma A.
    Assignee(s): Wyeth Holdings Corporation
    The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.
    Patent expiration dates:
    • April 9, 2016
      Drug substance
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.